e-ISSN: 2961-6204, p-ISSN: 2961-6123

Available online on http://www.ijhacr.com

International Journal of Health Advancement and Clinical Research (tz) 2023; 1(4); 85-89

Review Article

Extended-Release Tablets: An Overview

Subhash Chandra [1], Vijay Sharma [2], Sunil Kumawat [3]

[1] Research Scholar, Goenka College of Pharmacy, Lachhmangarh, Sikar.

[2] Professor, Goenka College of Pharmacy, Lachhmangarh, Sikar.

[3] Associate Professor, Goenka College of Pharmacy, Lachhmangarh, Sikar.

Received: 10-08-2023 / Revised: 13-09-2023 / Accepted: 26-10-2023
Corresponding author: Subhash Chandra
Conflict of interest: Nil

Abstract:

Extended-release tablets have become a cornerstone of modern pharmaceutical drug delivery. They offer numerous advantages over immediate-release formulations, such as reduced dosing frequency, improved patient compliance, and minimized side effects. This review article discusses the key concepts, advantages and disadvantages. Here is an overview of the general steps and considerations involved in the formulation of extended-release tablets. The applications of extended-release tablets are continually expanding as pharmaceutical research and development aim to improve patient adherence, reduce side effects, and enhance the overall quality of treatment.

Key Words: Extended-release tablets, Patient compliance, Patient adherence.

Introduction

The oral route is the most often utilized route for drug administration, owing to its convenience of administration and the fact that gastrointestinal physiology allows for more flexibility in dosage form formulation than most other routes. Sustained release, prolonged release, modified release, extended release, or depot formulations are terms used to describe drug delivery systems that are designed to achieve or extend therapeutic effect by continuously releasing medication after administration of a single dose over an extended period of time. [1]

There are several reasons why these dosage forms are appealing: they increase the bioavailability of the drug product, reduce the frequency of administration to extend the duration of effective blood levels, reduce the fluctuation of peak trough concentration and side effects, and possibly improve the specific distribution of the drug. Two prerequisites must be met in order to create an optimum medication delivery system: To begin, a single dosage for the course of therapy, whether for days or weeks, as in the case of infection, diabetes, or hypertension. Second, it should convey the active entity to the site of action while reducing side effects. [2]

Key Features of Extended-Release Tablets: [3,4]

- **Prolonged Drug Delivery:** Extended-release tablets are designed to provide a sustained release of medication over an extended period, which can range from a few hours to several days. This contrasts with immediate-release tablets, which release their contents rapidly.

- **Reduced Dosing Frequency:** One of the primary benefits of extended-release tablets is the reduction in dosing frequency. Patients often need to take these tablets less frequently, leading to improved adherence to treatment regimens.
- **Minimized Peak and Trough Effects:** Extended-release formulations aim to maintain a relatively constant drug concentration in the bloodstream, reducing the high peaks and low troughs associated with immediate-release drugs. This helps minimize side effects and improve therapeutic efficacy.
- **Improved Patient Compliance:** The reduced need for frequent dosing simplifies medication schedules, making it easier for patients to comply with their treatment plans.
- **Enhanced Safety Profile:** For drugs with a narrow therapeutic index, maintaining steady drug levels is crucial in preventing adverse events. Extended-release tablets can help achieve this.

Advantages of Extended-Release Delivery System [5]

a. Drug dose frequency is reduced with extended-release formulations.

b. Therapeutic concentrations may be maintained in prolonged release formulations.

c. Slowing medication absorption helps to reduce toxicity.

d. Using these formulas prevents elevated blood concentrations.

e. Long-acting formulations offer the potential to increase patient compliance and convenience.

Extended-Release Delivery System Drawbacks [6]

a. Extended release formulations have a larger drug load and consequently any loss of the dosage form's release properties.

b. The greater size of prolonged release products may make ingestion / transit through the intestines more challenging.

c. Food and the pace of transit through the stomach are two variables that influence release rates.

d. There are some variances in release rate across doses, however these have been decreased by contemporary formulations.

Mechanisms of Extended Release: [7]

Extended-release tablets employ various mechanisms to control drug release, including:

- **Diffusion-Controlled Systems:** Drug molecules are dispersed within a matrix, and release occurs as the drug diffuses through the matrix.
- **Osmotic Controlled Systems:** These systems use osmotic pressure to drive drug release. An osmotic core pushes the drug out of the tablet at a controlled rate.
- **Erosion-Controlled Systems:** Tablets with erosion-controlled release dissolve or erode gradually, releasing the drug as the tablet disintegrates.

Formulation of Extended Release Tablets [8,9,10]

Formulating extended-release tablets is a complex process that involves selecting appropriate excipients, controlling drug release mechanisms, and ensuring the tablets meet regulatory and quality standards. Here is an overview of the general steps and considerations involved in the formulation of extended-release tablets:

A. Selection of the Active Pharmaceutical Ingredient (API): The first step in formulating extended-release tablets is selecting the drug

compound that needs to be delivered in a controlled manner. The drug's physicochemical properties, solubility, and release characteristics are crucial factors.

B. Drug Release Mechanism: Choose the appropriate drug release mechanism based on the drug's properties and desired release profile. Common mechanisms include:

- **Diffusion-Controlled:** The drug is released through diffusion within a matrix or membrane.
- **Osmotic-Controlled:** Osmotic pressure forces the drug out of the tablet through a delivery orifice.
- **Erosion-Controlled:** The tablet erodes gradually, releasing the drug as it disintegrates.

C. Selection of Excipients: Excipients are non-active ingredients used to formulate the tablet. They include binders, fillers, disintegrants, lubricants, and other components that influence tablet properties. Excipients should be chosen carefully to ensure they are compatible with the extended-release mechanism.

D. Matrix Formation: For diffusion-controlled and erosion-controlled systems, the API and excipients are typically mixed and compressed into a tablet. For osmotic-controlled systems, a semi-permeable membrane surrounds the drug core.

E. Polymer Selection: In some cases, extended-release tablets use polymers to modulate drug release. Hydrophilic or hydrophobic polymers can be used to control the rate of water penetration and drug diffusion.

F. Compatibility Testing: Ensure that the API, excipients, and polymers are compatible and do not interact adversely. Compatibility studies are important to avoid chemical instability.

G. Evaluation of Drug Release Profile: Perform in vitro dissolution testing to assess the release profile of the tablet under simulated physiological conditions. The release rate should align with the desired therapeutic effect.

H. Regulatory Considerations: Comply with regulatory requirements regarding the safety, quality, and efficacy of the formulation. This includes Good Manufacturing Practices (GMP) and meeting specific standards set by regulatory authorities such as the FDA or EMA.

I. Quality Control: Regular quality control tests are essential to ensure uniformity in the tablet formulation. Tests may include weight variation, hardness, friability, disintegration, and dissolution testing.

J. Scale-Up and Manufacturing: Once the formulation is optimized, the manufacturing process can be scaled up for commercial production. This involves the production of a large quantity of extended-release tablets while maintaining quality and consistency.

K. Clinical Trials: If the formulation is for a new drug or a significant modification of an existing drug, clinical trials are typically conducted to assess safety and efficacy in human subjects.

L. Packaging: Proper packaging is essential to protect the tablets from environmental factors, moisture, and light. Packaging also ensures that the tablets maintain their extended-release properties over their shelf life.

Application of Extended-Release Tablets [11,12,13]

Extended-release tablets have a wide range of applications in the field of pharmaceuticals, and they are used in various therapeutic areas to deliver medications in a controlled and sustained

manner. Some of the key applications of extended-release tablets include:

a) **Pain Management:** Extended-release opioid medications are commonly used to provide long-lasting pain relief for patients suffering from chronic pain conditions, such as cancer pain or chronic back pain. These formulations allow for consistent pain control over an extended period, reducing the need for frequent dosing.

b) **Psychiatric Disorders:** Medications used to treat psychiatric disorders, such as depression and schizophrenia, often come in extended-release formulations. These tablets provide a continuous and stable release of the drug, helping to manage symptoms and improve patient adherence to treatment plans.

c) **Cardiovascular Diseases:** Extended-release tablets are used for medications that treat heart conditions, including hypertension and angina. They help maintain stable blood pressure and reduce the risk of cardiovascular events.

d) **Gastrointestinal Conditions:** Medications for gastrointestinal disorders like acid reflux, ulcers, and irritable bowel syndrome can benefit from extended-release tablets. These formulations help provide sustained relief from symptoms and reduce the frequency of dosing.

e) **Diabetes:** Extended-release formulations of insulin and other antidiabetic agents are used to regulate blood glucose levels in patients with diabetes. By providing a gradual release of the medication, these tablets mimic the body's natural insulin secretion.

f) **Neurological Disorders:** Extended-release tablets are used in the treatment of various neurological disorders, including epilepsy, Alzheimer's disease, and Parkinson's disease. These formulations help manage symptoms and improve the patient's quality of life.

g) **Respiratory Conditions:** Extended-release bronchodilators and corticosteroids are used to treat chronic respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). They ensure consistent bronchodilation and symptom control throughout the day.

h) **Chronic Pain Management:** In addition to opioids, extended-release formulations are used for non-opioid analgesics in chronic pain management. These tablets provide relief over an extended period, reducing the risk of addiction and side effects associated with immediate-release drugs.

i) **Hormone Replacement Therapy:** Hormone replacement therapy for menopausal women often includes extended-release tablets to deliver hormones steadily and manage symptoms like hot flashes and mood swings.

j) **Anti-Infective Agents:** Some antibiotics and antiviral medications are available in extended-release formulations. These are used to maintain effective drug concentrations in the body to combat infections.

Conclusion

Extended-release tablets represent a significant advancement in pharmaceutical drug delivery. Their ability to provide extended drug release, enhance patient compliance, and reduce side effects has led to their widespread use in a variety of therapeutic areas. With ongoing research and innovation, extended-release tablets will continue to play a pivotal role in the treatment of various medical conditions, improving the quality of life for countless patients.

References

1. Sanapa V, Vadakb S, Pande V, A Review on Extended-Release Drug Delivery System and Multiparticulate System, JETIR 2020; 7(4):1273-1287.

2. Barzeh A, Sogali B.S, Shadvar S, A Review on Extended Release Matrix Tablet, Journal of Pharmaceutical Research, 2016; 15(4): 147-152.
3. Madhusudhan P and Nazeer S. Extended-release formulation. International Journal of Pharmacy and Technology. 2010; 2: 625- 684.
4. Shalaka D, et al. Effect of Two Different Diluents on Release Profile of Aceclofenac from Sustained Release Matrix Tablets Using Gum Damar as Release Retardant. International Journal of Pharmacy and Pharmaceutical Sciences. 2011; 3(4): 307-313.
5. Reddy D.V, Rao A.S. A Review on Oral Extended-Release Technology. Research J. Pharm. and Tech.,2015; 8(10):1454-1462.
6. Chauhan M., Suthar S., Bilayer tablet: Immediate Release and Sustain Release: A Review, Research Journal of Pharmacy and Technology, 2012; (5): 716-720.
7. Patel KK, et al. An Overview: Extended Release Matrix Technology. International Journal of Pharmaceutical and Chemical Sciences. 2012; 1(2): 828-843.
8. Fabre LF and Timmer CJ. Effects of food on the bioavailability of gepirone from extended-release tablets in humans, results of two open-label crossover studies. Current Therapeutic Research. 2003; 64: 580-598.
9. Shah S.J, Shah P.B, Patel M.S, Patel M.R, A Review on Extended Release Drug Delivery System and Multiparticulate System, World Journal of Pharmaceutical Research, 2015; 4(8): 724-747.
10. Lin AY. A Study of the Effects of Curing and Storage Conditions on Extended Release Diphenhydramine HCl Pellets Coated with Eu-dragit®NE30D, Pharmaceutical Development and Technology; 2003; 8: 277-287.
11. Scott DC., Hollenbeck RG. Design and manufacture of a zero-order extended release pellet dosage form through non uniform drug distribution in a diffusional matrix, Pharmaceutical Research; 1991; 8(5): 156-161.
12. Haresh M, Thimmasetty J, Ratan G N. Formulation development and in-vitro evaluation of sustained release matrix tablets of risperidone. Inventi Impact Pharm Tech. 2013;1:28-34.
13. Ehab Ahmed MH. Ph.D. Thesis: Application and evaluation of extended release technology to loop diuretics. University of Cincinnati. 2002: 78-82.